Biogen Inc. (BIIB)

281.14
NASDAQ : Health Technology
Prev Close 278.14
Day Low/High 276.24 / 282.33
52 Wk Low/High 215.78 / 338.87
Avg Volume 1.67M
Exchange NASDAQ
Shares Outstanding 180.44M
Market Cap 50.19B
EPS 21.60
P/E Ratio 9.90
Div & Yield N.A. (N.A)

Latest News

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record

Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record

A lot of the names that fell hard after the Clinton impeachment have been record earners since then.

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Breaking down an approach to the long side of this biotech stock.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Biogen Raised at Bernstein

Biogen Maintained at Neutral at JPMorgan

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

We Have a Market That Has Become a Little Extended

We Have a Market That Has Become a Little Extended

This looks like a normal pause within an uptrend.

Biogen Stock Soars on Alzheimer's Drug News

Biogen Stock Soars on Alzheimer's Drug News

BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.

China Trade Optimism, Do Boeing's Numbers Matter? Trading Apple: Market Recon

China Trade Optimism, Do Boeing's Numbers Matter? Trading Apple: Market Recon

There is a chance that Presidents Trump and Xi sign something when they meet up at the APEC summit this November in Santiago, Chile.

No Shortage of Candidates for the Next Portfolio of Losers

No Shortage of Candidates for the Next Portfolio of Losers

Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

High Flyers and Low Flyers

Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...

Now at the Plate, Your Pinch Hitter, Bret Jensen

I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...

Release Your 'Inner Spock' When Investing in Biotech Stocks

Release Your 'Inner Spock' When Investing in Biotech Stocks

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

Biogen Could Rally in the Weeks Ahead

Biogen Could Rally in the Weeks Ahead

Buyers have returned in recent months and the stock could be ready to rise.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Time to Get Back to What I Do Best: Shorting Stocks

Time to Get Back to What I Do Best: Shorting Stocks

After a five-year hiatus I'm ready to start throwing whammies in several directions.